Post-earnings recap
Reported
Wed, Apr 26, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss per share of $0.25, slightly missing expectations. The stock fell by 1.66% following the announcement, reflecting investor concerns about the lack of revenue guidance and the overall financial performance. The absence of specific future guidance may lead to uncertainty among investors as the company continues its clinical programs.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.25 | N/A | -4.17% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing clinical development without offering specific financial guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on advancing its clinical programs despite the current financial results.